Westfield-based company receives expedited FDA review for insulin-delivery device
The “breakthrough” designation is intended to speed development and expedite review by federal regulators, especially for critical diseases.
Diabetes
-
Lilly to spend up to $1.93 billion to acquire Boston biopharmaceutical firm
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
Read More -
California to sue Lilly, other drug companies over insulin prices
California on Thursday announced it will sue the companies that make and promote most of the nation’s insulin, accusing them of scheming to illegally increase the price of the drug.
Read More -
FDA approves Lilly diabetes drug that helps patients lose weight
The drug has been closely watched by medical professionals and is viewed by financial analysts as a possible blockbuster, with potential annual sales in the billions of dollars.
Read More -
Lilly says experimental drug helped patients lose up to 22% of body weight
The drug, called tirzepatide, has been closely watched by medical professionals and is viewed by financial analysts as possible blockbuster, with potential annual sales in the billions of dollars.
Read More
Articles
Lilly’s Mounjaro gets mixed results in extensive study vs. Trulicity
A trial of Eli Lilly and Co.’s blockbuster diabetes drug Mounjaro fell short of expectations in one aspect, but the results showed enough cardio benefits to eventually encourage investors.
Weight-loss drugs may lower cancer risk in people with diabetes, study suggests
The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting.
Lilly stock soars after weight-loss pill’s trial results rival Ozempic’s shot
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Eli Lilly’s weight-loss drugs no longer in shortage, FDA says
Lilly has been making the case since August that its tirzepatide-based drugs are now “commercially available,” which the FDA agreed on. But the agency warned that patients and prescribers might still experience “localized supply disruptions.”
Eli Lilly ramps up fight against imitation weight-loss drugs
Lilly and rival Novo Nordisk have been battling the emerging industry making copies of their top-selling diabetes and weight-loss drugs, a situation without modern precedent.
Lilly now selling vials of blockbuster Zepbound at 50% discount
Lilly said its new option will help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.
Study: Lilly’s Zepbound cut risk of diabetes by 94% in obese people
The longest continuous study of Indianapolis-based Lilly’s drug Zepbound to date included more than 1,000 patients.
FDA warns against smartwatches, rings that claim to measure blood sugar without needles
About 37 million American have diabetes, which requires close monitoring of blood sugar levels. A doctor said using the unapproved devices could result in inaccurate blood sugar measurements, with potentially devastating consequences.
Lilly launches online service that offers home delivery of weight-loss, diabetes, migraine drugs
Among the medications listed as available through LillyDirect Pharmacy Services is Zepbound, the company’s popular new weight loss treatment, which is projected to exceed $2 billion in sales in 2024.
Shedding fat without losing muscle is Lilly’s next weight-loss target
Eli Lilly and Co. will study its blockbuster diabetes drug Mounjaro in combination with an experimental muscle-loss treatment as it searches for ways to help patients maintain muscle while losing weight.
Lilly stock soars to all-time high on strong sales, led by Mounjaro
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
Next step for obesity drug makers replacing needles with pills
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
Eli Lilly settles class-action insulin lawsuit for $13.5M
Under the agreement, Lilly has agreed to continue its cap on out-of-pocket costs for its users at $35 a month for four years.
Lilly diabetes drug helps patients shed average of 34 pounds, a development sure to boost sales
The Indianapolis-based drugmaker said it would complete submission of tirzepatide to the U.S. Food and Drug Administration in coming weeks for treatment of obesity and expects regulatory action as early as late 2023.
Following Lilly’s lead, Novo Nordisk plans insulin price cuts
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly and Co.
With stock trading near record high, Lilly embarks on ambitious 2023
The Indianapolis-based pharmaceutical company is preparing for one of its most ambitious years in memory for 2023, with plans to advance five new drugs into late-stage clinical studies and move four into regulatory review.
Diabetes drug Lilly abandoned has new life
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
Insulin cap for Medicare patients signals hope for others
In January, the cost of insulin for patients on Medicare will be capped at $35 a month. But that cap doesn’t apply to those with private insurance, which is used by the majority of those in need of insulin.
House passes $35-a-month insulin cap as Dems seek wider bill
The Affordable Insulin Now Act will serve as a political vehicle to rally Democrats and force Republicans who oppose it into uncomfortable votes ahead of the midterms.